The last post in our risk management series discussed the relationship between issues and risks—namely, that a quality issue can elevate an existing risk or serve as a harbinger of a new risk. When an issue occurs, it’s not enough to react to the problem – we also need to anticipate the ripple effects.
Caleb Barlow, CEO of CynergisTek details in this article the COVID-19 pandemic increased risk of cyberattacks for clinical trial sponsors and vendors and describes how cyberattacks have evolved over the last several years, and why we should be preparing for one.
Click here to read the full story.
